Our data were found in patients with unknown resistance to treatment, and although the number of patients was low and data were precursory, in the evolution of EGFR-mutated lung cancer, NF1 could be playing an unknown role in disease progress and resistance to targeted therapies. The gene discussed is EGFR; the disease is lung carcinoma.